TiGenix secures Spanish reimbursement for ChondroCelect

The Spanish Health Authority has informed TiGenix that its cartilage repair therapy, ChondroCelect, will obtain national reimbursement in Spain. The company obtained national reimbursement in the Netherlands in 2012 and will continue working to obtain national reimbursement in other European countries later in 2013.

Currently, ChondroCelect is the first and the only cell therapy that has been granted market authorisation by the EU in accordance with the Advanced Therapy Medicinal Product regulation.

TiGenix secures Spanish reimbursement for ChondroCelect

The Spanish Health Authority has informed TiGenix that its cartilage repair therapy, ChondroCelect, will obtain national reimbursement in Spain. The company obtained national reimbursement in the Netherlands in 2012 and will continue working to obtain national reimbursement in other European countries later in 2013.

Currently, ChondroCelect is the first and the only cell therapy that has been granted market authorisation by the EU in accordance with the Advanced Therapy Medicinal Product regulation.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.